BDSX vs BIAF

Biodesix, Inc. vs bioAffinity Technologies, Inc. — Valuation Comparison 2026

BDSX

Diagnostics & Research
Biodesix, Inc.
Quality
6.0
out of 10
Value Trap
30
LOW
Price
$15.99
Last close
Models
8/13
Active
VS

BIAF

Diagnostics & Research
bioAffinity Technologies, Inc.
Quality
4.7
out of 10
Value Trap
49
WARN
Price
$1.65
Last close
Models
10/13
Active

Model-by-Model Comparison

ModelType BDSX Fair ValueBDSX Upside BIAF Fair ValueBIAF Upside
Bayesian DCF Intrinsic $1.93 -88.0% $0.71 -56.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.50 -95.5% $0.18 -91.8%
Dynamic NAV Asset-Based $0.47 -96.7% $1.22 -26.3%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for BDSX vs BIAF — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BDSX vs BIAF — Which Stock Is More Undervalued?

BDSX scores higher with a 6.0/10 quality rating vs BIAF's 4.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Biodesix, Inc. (BDSX) and bioAffinity Technologies, Inc. (BIAF) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BDSX currently trades at $15.99 with a QOC of 6.0/10, while BIAF trades at $1.65 with a QOC of 4.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).